And all of the AGN concerns pushed aside. DARPin macular degeneration drug that competes with Regeneron's (REGN) EYLEA. Latisse scalp timing being pushed out Restasis generic competition. And recently, tissue nutrient solution, a skin-care product line containing human growth factors obtained from human foreskin tissue that could increase the risk of cancer and pose other health risks. Not a problem let's add 5 Billion to the market cap in 5 days? Be selling with two fists into this!